# Secondary alopecia due to semaglutide.

> PubMed lists PMID 42364353 in Medicina clinica as Letter, with publication-date metadata of 2026-06-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42364353-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42364353-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42364353-semaglutide-v1.json
- Content SHA-256: `f0fa838a6869cfc3223faf8b98dfeca5e2f8566d7cd399e613c59584743e0656`

## Claims and source pins

### Headline

Secondary alopecia due to semaglutide. ([`pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044`](#source-pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044))

### Summary

PubMed lists PMID 42364353 in Medicina clinica as Letter, with publication-date metadata of 2026-06-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044`](#source-pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044))

### Paragraph 1

PubMed lists PMID 42364353 in Medicina clinica as Letter, with publication-date metadata of 2026-06-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044`](#source-pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044`](#source-pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044))

## Sources

<a id="source-pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044"></a>
- **Secondary alopecia due to semaglutide. · retained source version 1:2026-06-27:current:fe397cdcc044c416140262cd61d154e87c2beca956d333a1be982c1e4f1b397a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42364353/) (`pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Secondary alopecia due to semaglutide." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42364353-semaglutide-v1.json SHA-256: f0fa838a6869cfc3223faf8b98dfeca5e2f8566d7cd399e613c59584743e0656.